Tumor cells accumulate aberrations not present in normal cells, leading to presentation of
neoantigens on MHC molecules on their surface. These non-self neoantigens distinguish
tumor cells from normal cells to the immune system and are thus targets for cancer
immunotherapy. The rapid development of molecular profiling platforms, such as next-
generation sequencing, has enabled the generation of large datasets characterizing tumor
cells. The simultaneous development of algorithms has enabled rapid and accurate …